REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis
USA - NASDAQ:REGN - US75886F1075 - Common Stock
583.01 USD
+3.67 (+0.63%)
We assign a fundamental rating of 7 out of 10 to REGN. REGN was compared to 534 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes REGN very considerable for value investing!
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
In the past year REGN had a positive cash flow from operations.
In the past 5 years REGN has always been profitable.
In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
REGN's Return On Assets of 11.67% is amongst the best of the industry. REGN outperforms 94.57% of its industry peers.
REGN has a Return On Equity of 14.89%. This is amongst the best in the industry. REGN outperforms 94.57% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.28%, REGN belongs to the top of the industry, outperforming 94.01% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for REGN is below the industry average of 15.49%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.67% | ||
| ROE | 14.89% | ||
| ROIC | 9.28% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
REGN's Profit Margin of 31.37% is amongst the best of the industry. REGN outperforms 96.25% of its industry peers.
REGN's Profit Margin has improved in the last couple of years.
REGN has a better Operating Margin (28.56%) than 96.44% of its industry peers.
REGN's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 86.46%, REGN belongs to the best of the industry, outperforming 88.95% of the companies in the same industry.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.56% | ||
| PM (TTM) | 31.37% | ||
| GM | 86.46% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
REGN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for REGN has been reduced compared to 5 years ago.
The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.82 indicates that REGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.82, REGN is in the better half of the industry, outperforming 76.40% of the companies in the same industry.
REGN has a debt to FCF ratio of 0.76. This is a very positive value and a sign of high solvency as it would only need 0.76 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.76, REGN belongs to the best of the industry, outperforming 95.32% of the companies in the same industry.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, REGN is not doing good in the industry: 63.48% of the companies in the same industry are doing better.
Although REGN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.76 | ||
| Altman-Z | 6.82 |
ROIC/WACC1.01
WACC9.2%
2.3 Liquidity
REGN has a Current Ratio of 4.60. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of REGN (4.60) is comparable to the rest of the industry.
REGN has a Quick Ratio of 3.93. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio (3.93) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.6 | ||
| Quick Ratio | 3.93 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.42% over the past year.
REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.38%.
REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.55% yearly.
EPS 1Y (TTM)2.42%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%11.51%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%3.62%
3.2 Future
REGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.81% yearly.
REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.26% yearly.
EPS Next Y-12.78%
EPS Next 2Y-4.06%
EPS Next 3Y3.32%
EPS Next 5Y5.81%
Revenue Next Year-2.02%
Revenue Next 2Y1.3%
Revenue Next 3Y4.35%
Revenue Next 5Y5.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 12.77 indicates a correct valuation of REGN.
REGN's Price/Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 97.38% of the companies in the same industry.
REGN is valuated cheaply when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 13.88, REGN is valued correctly.
95.51% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
REGN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.77 | ||
| Fwd PE | 13.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.88% of the companies listed in the same industry.
REGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. REGN is cheaper than 95.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.38 | ||
| EV/EBITDA | 11.2 |
4.3 Compensation for Growth
The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.97
EPS Next 2Y-4.06%
EPS Next 3Y3.32%
5. Dividend
5.1 Amount
With a yearly dividend of 0.62%, REGN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 93.65, REGN pays a better dividend. On top of this REGN pays more dividend than 98.31% of the companies listed in the same industry.
With a Dividend Yield of 0.62, REGN pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.62% |
5.2 History
REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-4.06%
EPS Next 3Y3.32%
NASDAQ:REGN (10/22/2025, 3:33:09 PM)
583.01
+3.67 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change0.02%
Ins Owners1.89%
Ins Owner Change0%
Market Cap61.79B
Revenue(TTM)14.21B
Net Income(TTM)4.46B
Analysts81.18
Price Target744.96 (27.78%)
Short Float %2.93%
Short Ratio2.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.62% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.56%
Min EPS beat(2)-8.66%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)12.63%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)8.06%
EPS beat(12)10
Avg EPS beat(12)9%
EPS beat(16)13
Avg EPS beat(16)9.97%
Revenue beat(2)1
Avg Revenue beat(2)0.2%
Min Revenue beat(2)-9.31%
Max Revenue beat(2)9.72%
Revenue beat(4)1
Avg Revenue beat(4)-0.28%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)8
Avg Revenue beat(12)1.29%
Revenue beat(16)12
Avg Revenue beat(16)3.14%
PT rev (1m)0%
PT rev (3m)-0.89%
EPS NQ rev (1m)-0.85%
EPS NQ rev (3m)4.76%
EPS NY rev (1m)-0.4%
EPS NY rev (3m)10.27%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)3.85%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)3.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.77 | ||
| Fwd PE | 13.88 | ||
| P/S | 4.35 | ||
| P/FCF | 17.38 | ||
| P/OCF | 13.03 | ||
| P/B | 2.06 | ||
| P/tB | 2.16 | ||
| EV/EBITDA | 11.2 |
EPS(TTM)45.64
EY7.83%
EPS(NY)42.01
Fwd EY7.21%
FCF(TTM)33.55
FCFY5.76%
OCF(TTM)44.75
OCFY7.68%
SpS134.11
BVpS282.47
TBVpS269.72
PEG (NY)N/A
PEG (5Y)0.97
Graham Number538.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.67% | ||
| ROE | 14.89% | ||
| ROCE | 11.75% | ||
| ROIC | 9.28% | ||
| ROICexc | 11.84% | ||
| ROICexgc | 12.46% | ||
| OM | 28.56% | ||
| PM (TTM) | 31.37% | ||
| GM | 86.46% | ||
| FCFM | 25.02% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.76 | ||
| Debt/EBITDA | 0.59 | ||
| Cap/Depr | 232.74% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.81% | ||
| Profit Quality | 79.76% | ||
| Current Ratio | 4.6 | ||
| Quick Ratio | 3.93 | ||
| Altman-Z | 6.82 |
F-Score5
WACC9.2%
ROIC/WACC1.01
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)2.42%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%11.51%
EPS Next Y-12.78%
EPS Next 2Y-4.06%
EPS Next 3Y3.32%
EPS Next 5Y5.81%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%3.62%
Revenue Next Year-2.02%
Revenue Next 2Y1.3%
Revenue Next 3Y4.35%
Revenue Next 5Y5.26%
EBIT growth 1Y-2.61%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y7.36%
FCF growth 1Y18.37%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y0.1%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%